Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (101-110 of 791) with videos related to

Pageof 80
Sort By:
Leukemia & Lymphoma|February 9, 2011
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Cancer Medicine|January 2, 2024
County-level colorectal cancer screening rates on colorectal cancer survival in the state of Georgia: Does county-level rurality matter?Meng-Han Tsai, Steven S Coughlin, Jorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemiaJorge Cortes, Andreas Hochhaus, Timothy Hughes, et al.
Drug Design, Development and Therapy|November 19, 2009
Development and targeted use of nilotinib in chronic myeloid leukemiaCarmen Fava, Hagop Kantarjian, Jorge Cortes, et al.
Expert Opinion on Pharmacotherapy|April 24, 2012
Tyrosine kinase inhibitors in acute and chronic leukemiasMaro Ohanian, Jorge Cortes, Hagop Kantarjian, et al.
Cancer Control : Journal of the Moffitt Cancer Center|July 1, 2025
Racial/Ethnic and Age-Related Disparities in Early-Onset Colorectal Cancer Diagnoses and SurvivalMeng-Han Tsai, Jorge Cortes, Kenneth J Vega
Cancer|October 21, 2010
Monitoring molecular response in chronic myeloid leukemiaJorge Cortes, Alfonso Quintás-Cardama, Hagop M Kantarjian
Cancer|October 6, 2010
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implicationsJavier Pinilla-Ibarz, Jorge Cortes, Michael J Mauro
Expert Opinion on Emerging Drugs|March 23, 2011
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaHillary Prescott, Hagop Kantarjian, Jorge Cortes, et al.
Expert Review of Hematology|June 15, 2011
Dasatinib for the treatment of chronic myeloid leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80

Showing results (101-110 of 791) with videos related to

Sort By:
Pageof 80
Leukemia & Lymphoma|February 9, 2011
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Cancer Medicine|January 2, 2024
County-level colorectal cancer screening rates on colorectal cancer survival in the state of Georgia: Does county-level rurality matter?Meng-Han Tsai, Steven S Coughlin, Jorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemiaJorge Cortes, Andreas Hochhaus, Timothy Hughes, et al.
Drug Design, Development and Therapy|November 19, 2009
Development and targeted use of nilotinib in chronic myeloid leukemiaCarmen Fava, Hagop Kantarjian, Jorge Cortes, et al.
Expert Opinion on Pharmacotherapy|April 24, 2012
Tyrosine kinase inhibitors in acute and chronic leukemiasMaro Ohanian, Jorge Cortes, Hagop Kantarjian, et al.
Cancer Control : Journal of the Moffitt Cancer Center|July 1, 2025
Racial/Ethnic and Age-Related Disparities in Early-Onset Colorectal Cancer Diagnoses and SurvivalMeng-Han Tsai, Jorge Cortes, Kenneth J Vega
Cancer|October 21, 2010
Monitoring molecular response in chronic myeloid leukemiaJorge Cortes, Alfonso Quintás-Cardama, Hagop M Kantarjian
Cancer|October 6, 2010
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implicationsJavier Pinilla-Ibarz, Jorge Cortes, Michael J Mauro
Expert Opinion on Emerging Drugs|March 23, 2011
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaHillary Prescott, Hagop Kantarjian, Jorge Cortes, et al.
Expert Review of Hematology|June 15, 2011
Dasatinib for the treatment of chronic myeloid leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.
Pageof 80